cancervax
-
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on…
-
CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside…
-
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue…
-
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment…
-
CancerVax Achieves Major Milestones and Files Foundational Patent Application
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform
-
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem…
-
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology
-
CancerVax Passes First Test with Flying Colors
Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch…
-
CancerVax Targets Hard to Treat Pancreatic Cancer
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide…
-
CancerVax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Vaccine Targeting Milestone
The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting…
-
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials
-
CancerVax Launches $5 Million Funding Round
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
